Rapamycin (Sirolimus) and Vaccines: What Every Woman Needs to Know About This Drug Interaction

What Rapamycin Actually Does to Your Immune System

Rapamycin blocks mTORC1, the mammalian target of rapamycin complex 1, a central regulator of cell growth and immune activation. In T lymphocytes this means blunted proliferation after antigen exposure. In B lymphocytes it means impaired class-switching and reduced antibody production. Both effects directly undercut the purpose of vaccination.

A 2014 randomized controlled trial published in Science Translational Medicine by Mannick et al. Found that low-dose RAD001 (everolimus, a rapamycin analogue) at 0.5 mg daily for six weeks enhanced influenza vaccine response in adults over 65 by roughly 20 percent compared with placebo. That finding is frequently cited to argue that low-dose mTOR inhibition is immunostimulatory. The nuance most longevity articles omit: the dose matters enormously, the population was elderly (not reproductive-age women), and full immunosuppressive doses used in transplant medicine consistently reduce vaccine immunogenicity.

The Dose-Response Curve Women Need to Understand

The transplant literature, which uses sirolimus trough levels of 4-12 ng/mL, shows consistent and sometimes severe attenuation of vaccine responses. Off-label longevity protocols typically target trough levels of 1-6 ng/mL on intermittent schedules (often 5 mg once weekly). Whether this lower exposure spares vaccine immunogenicity the way the Mannick data suggested is not yet established in prospective trials in women.

Why Women's Immune Biology Adds Complexity

Women mount stronger innate and adaptive immune responses than men across most of adult life. Estrogen upregulates toll-like receptor signaling, increases antibody titers after vaccination, and amplifies inflammatory responses. This is why women report injection-site reactions, fever, and fatigue after flu and COVID-19 vaccines at approximately twice the rate of men. Sirolimus partially suppresses these estrogen-amplified immune pathways. During perimenopause and postmenopause, when estrogen falls, baseline vaccine immunogenicity is already declining, so adding mTOR inhibition may compound the deficit.

Live Vaccines: A Hard Stop

Live attenuated vaccines are contraindicated on sirolimus. The FDA prescribing label for sirolimus states clearly that live vaccines should be avoided during treatment and for an appropriate interval after stopping.

Live vaccines relevant to women include:

• MMR (measles, mumps, rubella), critical for reproductive-age women and for pre-conception immunity
• Varicella (chickenpox) and zoster (Shingrix is an inactivated recombinant vaccine and IS permitted; the older live zoster vaccine Zostavax is not)
• Yellow fever
• Intranasal influenza (FluMist)

If you are a woman of reproductive age on sirolimus who has never had varicella or whose MMR titers are low, you face a clinical challenge. Neither the MMR nor the varicella vaccine can be given safely while you remain on the drug. Stopping sirolimus, waiting a sufficient washout period (generally accepted as at least two to four weeks given its roughly 62-hour half-life, though immunosuppression may persist longer), getting the live vaccine, and then restarting is the most common clinical approach, but this must be discussed with your prescribing clinician because washout and immune recovery timelines vary by prior duration of exposure and individual pharmacokinetics.

Inactivated and Subunit Vaccines: Permitted But Attenuated

Inactivated vaccines can be given while you are on sirolimus. The question is whether they will work well enough.

Influenza

Annual flu vaccination is recommended for all women on immunosuppressive therapy. A study in kidney transplant recipients on sirolimus-based regimens found seroprotection rates of roughly 40-60 percent after standard-dose influenza vaccine, compared with 70-80 percent in healthy controls. High-dose or adjuvanted influenza vaccines (Fluzone High-Dose, Fluad) are often preferred for immunocompromised patients and may partially compensate for the blunted response, though head-to-head data in sirolimus-only users are limited.

COVID-19

SARS-CoV-2 mRNA vaccine immunogenicity is reduced in solid-organ transplant recipients on mTOR inhibitors. A multicenter study published in JAMA in 2021 found that only 17 percent of transplant patients on immunosuppression achieved antibody levels considered protective after two doses, compared with near-universal seroconversion in healthy controls. Most solid-organ transplant guidelines now recommend a three-dose primary series plus bivalent boosters for patients on mTOR inhibitors and calcineurin inhibitors. If you are using sirolimus off-label for longevity at a lower dose, your attenuation may be less severe, but no published trial has measured this in healthy women specifically.

HPV

For younger women and for women under 45 who are eligible for catch-up HPV vaccination, sirolimus should not be assumed to negate benefit entirely, but reduced immunogenicity is likely. Complete your HPV series before starting sirolimus if possible.

Shingrix (Recombinant Zoster Vaccine)

Shingrix is an adjuvanted recombinant subunit vaccine, not live, and is safe to administer on sirolimus. The CDC ACIP recommendations suggest Shingrix for adults 50 and older and for immunocompromised adults 19 and older. Women on chronic sirolimus therapy should discuss early Shingrix vaccination with their clinician given the known risk of herpes zoster reactivation in immunosuppressed patients.

Pneumococcal Vaccines

ACOG and the CDC recommend pneumococcal vaccination for immunocompromised women. Sirolimus likely attenuates the antibody response, but vaccination is still recommended because partial protection is better than none. The current US schedule recommends PCV20 or PCV15 followed by PPSV23 for immunocompromised adults.

Timing Strategies to Maximize Vaccine Protection

Getting the timing right is the single most actionable thing you can do to improve vaccine responses while using sirolimus.

The following framework is used at WomanRx to counsel women on sirolimus about vaccination timing. It is based on transplant immunology guidelines, the sirolimus pharmacokinetic label, and published immunogenicity data, adapted for the lower doses and intermittent schedules common in off-label longevity use:

Pre-start window (ideal): Complete all live vaccines at least four weeks before your first sirolimus dose. Complete inactivated and subunit vaccines at least two weeks before. This allows full immune priming before mTOR inhibition begins.

Mid-treatment (ongoing): Schedule annual inactivated flu and COVID-19 booster vaccinations on days when you have the longest interval since your last sirolimus dose. For weekly dosing, vaccinate on day six or seven of that week, immediately before your next scheduled dose. This exploits the trough in drug concentration and may allow a slightly more strong early immune response in the 24-72 hours after vaccine administration.

Pause-and-vaccinate (for live vaccines only): If you need a live vaccine while on sirolimus, the clinical default is to stop sirolimus, allow at least four weeks of washout (longer for high trough levels), administer the vaccine, wait two to four additional weeks for the immune response to develop, and then restart. Do not attempt this without clinician supervision, and confirm immunity by post-vaccine titer testing before restarting.

Post-vaccine titer testing: Given reduced immunogenicity, consider asking your clinician for post-vaccination antibody titers (especially for COVID-19, hepatitis B, and varicella/VZV) to confirm you have achieved meaningful seroprotection. This is standard practice in solid-organ transplant centers and is reasonable for any woman on chronic sirolimus at immunosuppressive doses.

Pregnancy, Lactation, and Contraception: Required Reading

This section is mandatory reading if you are pregnant, breastfeeding, or could become pregnant.

Pregnancy

Sirolimus is FDA Pregnancy Category C, meaning animal studies have shown embryotoxicity and reduced fetal weight at doses below the human therapeutic dose, and adequate human controlled studies do not exist. In transplant recipients, sirolimus has been associated with impaired healing of uterine anastomoses and pregnancy complications. Most transplant nephrology and maternal-fetal medicine guidelines recommend switching from sirolimus to a calcineurin inhibitor before conception.

The European Best Practice Guidelines on pregnancy in renal transplantation explicitly recommend discontinuing mTOR inhibitors before attempting conception.

If you are taking sirolimus off-label for longevity, PCOS management, or any other indication, you should use reliable contraception throughout treatment. Sirolimus does not reliably substitute for contraception. Hormonal contraceptives (combined oral contraceptives, progestin-only pills, hormonal IUDs) are generally compatible with sirolimus, though CYP3A4-metabolized contraceptives may have slightly altered pharmacokinetics given sirolimus's inhibition of this pathway at higher doses. A copper IUD provides hormone-independent contraception without this theoretical interaction.

If you discover you are pregnant while on sirolimus, contact your prescribing clinician the same day. Do not abruptly stop without guidance, but the general recommendation is to discontinue as early in pregnancy as possible.

Lactation

Sirolimus transfers into human breast milk. A case report published in Transplantation documented detectable sirolimus levels in the breast milk of a transplant recipient. Given the immunosuppressive potential in a newborn whose immune system is still maturing, breastfeeding is not recommended while taking sirolimus at any dose. The American Academy of Pediatrics and most transplant guidelines classify sirolimus as incompatible with breastfeeding.

If you are postpartum and were on sirolimus before pregnancy and wish to restart, discuss with your clinician whether formula feeding from birth allows an earlier restart timeline, balanced against the known benefits of breastfeeding.

A Note on Fertility

MTOR signaling is involved in folliculogenesis and ovarian reserve. Animal data suggest that chronic mTOR inhibition may impair ovarian response. One small study in women with premature ovarian insufficiency found that rapamycin did not rescue ovarian function at the doses studied. If you are trying to conceive, sirolimus should be discontinued before attempting pregnancy, and you should discuss ovarian reserve monitoring (AMH, antral follicle count) with your reproductive endocrinologist.

Women-Specific Conditions Where Rapamycin Is Used Off-Label

PCOS

Some clinicians prescribe low-dose sirolimus off-label for PCOS, reasoning that mTOR inhibition may reduce the hyperactivation of primordial follicles seen in some PCOS phenotypes. A 2022 review in Fertility & Sterility noted that mTOR pathway dysregulation is measurable in PCOS ovaries, but clinical trial data supporting sirolimus as a PCOS treatment are absent. If you are offered this off-label use, you should receive clear informed consent about the experimental nature of the indication and the vaccine interaction risks described in this article.

Perimenopause and Longevity Use

The fastest-growing off-label use of low-dose rapamycin is in women 40-60 using it as a longevity drug, often self-prescribed or obtained through concierge medicine. Interest spiked after the ITP (Interventions Testing Program) mouse lifespan data showed extended median lifespan in both male and female mice treated with rapamycin starting at 600 days of age, which corresponds roughly to late middle age. Human longevity trial data in women do not yet exist. The PEARL trial (a phase 2 RCT of low-dose sirolimus in healthy older adults) has published interim immunology data but has not yet reported primary longevity endpoints.

For perimenopausal women using rapamycin, the vaccine interaction profile described in this article applies regardless of dose. Lower doses likely cause less attenuation than transplant-level doses, but the direction of the effect is the same.

Tuberous Sclerosis Complex (TSC)

Women with TSC are often prescribed sirolimus long-term for renal angiomyolipomas and pulmonary lymphangioleiomyomatosis (LAM). The LAM Foundation and the Tuberous Sclerosis Alliance both recommend that patients on sirolimus receive age-appropriate vaccinations on standard schedules, with the explicit acknowledgment that live vaccines are contraindicated and that antibody responses may be reduced. The MILES trial of sirolimus in LAM enrolled exclusively women and reported no vaccine-specific safety signals during the 12-month treatment period, though immunogenicity was not a measured endpoint.

Drug and Supplement Interactions That Compound Vaccine Risk

Sirolimus is metabolized by CYP3A4 and is a substrate of P-glycoprotein. Several common medications and supplements used by women significantly alter sirolimus blood levels, which in turn affects the degree of immunosuppression and therefore vaccine response.

Drugs that raise sirolimus levels (increase immunosuppression and vaccine attenuation):

• Fluconazole and other azole antifungals (frequently prescribed for vaginal candidiasis)
• Clarithromycin
• Diltiazem and verapamil
• Grapefruit juice (approximately 1-3 fold increase in AUC)

Drugs that lower sirolimus levels (reduce efficacy):

• Rifampin
• Carbamazepine
• St. John's Wort (a common supplement used for perimenopausal mood symptoms; the FDA has warned about this interaction)
• Phenytoin

If you are prescribed fluconazole for a yeast infection while on sirolimus, your sirolimus level may spike. Schedule any planned vaccination after fluconazole clearance (typically five to seven days after the last dose) to avoid measuring vaccine immunogenicity during peak drug elevation.

Who This Is Right For and Not Right For, by Life Stage

Reproductive years (18-40), trying to conceive: Sirolimus is not appropriate. Discontinue before attempting conception. Ensure live vaccine immunity (MMR, varicella) is confirmed by titer before starting sirolimus for any indication and before you stop contraception.

Reproductive years, not planning pregnancy: Use reliable contraception throughout. Optimize vaccine timing as described in the timing framework above. Annual flu, up-to-date COVID-19 boosters, and HPV completion (if under 45) should be prioritized.

Perimenopause (roughly 40-55): The most common longevity-use demographic. Falling estrogen already reduces vaccine immunogenicity somewhat. Discuss high-dose or adjuvanted flu vaccine with your clinician. Shingrix series should be completed at 50 or at the start of sirolimus therapy, whichever comes first.

Postmenopause (55+): Pneumococcal vaccination series and annual respiratory virus vaccines are especially important given compounded immunosenescence plus mTOR inhibition. RSV vaccine (Abrysvo, Arexvy) is now recommended for adults 60+ and is an inactivated subunit vaccine, so it is permitted on sirolimus.

Women with autoimmune conditions: Women use immunosuppressants including sirolimus for conditions like lupus nephritis and rheumatoid arthritis. The vaccine timing framework here applies, and rheumatology society guidelines (ACR vaccine guidance) generally mirror the transplant approach. Coordinate with your rheumatologist before any vaccination.

Alcohol and Sirolimus: The Brief Answer

Can you drink on sirolimus? Alcohol does not directly inhibit CYP3A4 in a clinically significant way for sirolimus metabolism, so one standard drink is unlikely to alter your sirolimus trough level meaningfully. The more practical concern is that alcohol impairs sleep, increases systemic inflammation, and transiently suppresses immune function, all of which work against the goal of a good vaccine response in the days after immunization. Many transplant centers recommend avoiding alcohol for 48-72 hours after vaccination for this reason, regardless of immunosuppressive regimen.

Heavy or chronic alcohol use is a separate issue. Alcohol use disorder is associated with significant immune dysregulation, which combined with sirolimus could further compromise vaccine responses and increase infection risk.

Questions to Ask Your Clinician Before Your Next Vaccine

A direct list of what to cover at your next appointment:

1. What is my current sirolimus trough level, and how does it affect my vaccination risk category?
2. Which vaccines am I behind on, and which are live versus inactivated?
3. Should I pause sirolimus around my flu or COVID-19 booster, and for how long?
4. Do I need post-vaccination titers to confirm seroprotection?
5. Is my contraception method reliable enough given the teratogenicity of sirolimus?
6. If I am perimenopausal and my last MMR was more than 20 years ago, should we check titers?

The Infectious Diseases Society of America (IDSA) guidelines on vaccination of immunocompromised hosts recommend that prescribing clinicians maintain a vaccination record for every immunosuppressed patient and review it at least annually. Ask your clinician whether this review is happening for you.